Denver Summary

8/8/2019 Denver Summary

http://slidepdf.com/reader/full/denver-summary 1/9

The Denver ExperimentQ4 2010

The Good, the bad, and the ugly



Cancer models for targeted drug discovery

horizondiscovery.com




horizondiscovery.comThe Good

Results hard:

Sourced contacts

-Collected 30 business cards

-Made at least 50 introductions

-Obtained participant contact details (247)

Sourced opportunities-Lawrence Berkely National Laboratories (CL licensing & collab.)

Qualified, PV = $50K

-Nodality (CL licensing)

-Jeffrey Sklar, Yale School of Medicine, (Gen Licensing or custom)

-MD Anderson Cancer Centre (CL licensing)

-Quest Diagnostics (CL licensing)

-PGx Health (CL licensing)

-BioChain Institute Inc. (Biz Dev Op)

-Centre for translational and applied genomics (CL licensing)





Results soft:

Achieved exposure

-disseminated 250-300 cell line catalogues

-made at least 50 introductions (providing business card and catalogue)

networked with organizers-Mehmet Toner (Harvard medical school)

-Gordon Mills (MD Anderson Cancer Center) ± provided me with:

-Dr. Jeff Rubens Contact details who we need to get to know for main conference





Education:

Identified new product opportunity (HDx)

-blood based Dx huge theme of conference

-platforms rely on imaging (both the industry standard and those in dev)

-imaging of phenotype determined by cell surface proteins linked to gene expression

-current controls rely on ATCC derived cells with majority marker expression(yet still heterogeneous and thus not good enough)

-gene targeting would enable homogenous pool of marker expressing cells

-these cells spiked in blood at varying conc. Points represent an unparalled controlfor both validation and batch control

Identified unmet promotional requirements- no tool representing the science underpinning Genesis

recommend booklet comprised of rAAV publication extracts and an unbiasedcomparitive anlaysis of competing techniques.(including those we currently don¶t address such as KO in MEF¶s and Lentivirus

-redesign of HDx offering required with scientific underpinning and a detailed scientific argumentof the value of HDx controls vs other.Eg need to commission study to show case reduction in false positives/false negatives





Education:

Learned a shit load about

-pathways,

-platform technologies,

-drug development,

-intelligent clinical trial design

-CDx development (technical, systemic, strategic barriers)makes me more competent

Identified potential mutations for new CL development-ERK

-JAZ, JJAZ (apoptosis)

-Runx3

-beta 1 and beta 3 integrin

-Lefty gene (nodal expression)

Identified error in case studies bookletangiogenesis assay page does not show angiogenesis assay (shows invasion assay)




horizondiscovery.comThe Bad

This was an academic conference-significant progress with key researchers

-not much exposure to biotech/pharma players

Embarrassed myself a few times when stumbling on presenting our technology-may have made a bad impression on HDlTD




horizondiscovery.comThe Ugly

failed to achieve target of elucidating market research for promega negotiation-missed opportunity to talk in person to LabTech CTO(Though I met someone who is happy to but me in touch)

-presence of ref lab players undetectable

Did manage to talk to Quest Diagnostics (one of the biggest agnostic ref labs) who confirmed that they wouldnot directly source controls from Suppliers but instead use the controls provided within kits by developers

not a direct opportunity for HDxtells us we should also be interviewing developers, not just ref labs.some ppl were looking at the prize draw survey I put together so we may get some completed ones back.




horizondiscovery.comConclusion

Fantastic experience and got alot out of it personally and for the company

it is an academic conference

It is essential to send Chris here next year to do a talk (we now have the connections to begin work on this)

Have taken notes and recording and a slide show about clinical trial intelligent design which I will shareWith you on the server

Validations

-the science sells itself, we can never have enough science, and we don¶t have enough to cover all our areasat the moment

-cell lines (non-isogenics) as translational tools were a prominent theme in the conference

-Mehmet Toner (Harvard - expert) thinks cell lines represent a huge financial opportunity;Ie. if someone discovers a drug with our lines we will be in business for life

Noteworthy

Nicholas Dracopoli (head of biomarker deve ortho Dx) in his talk predicted business model innovation to foster CDx development through revenue share from sale of personalised drugs.

Novartis has just launched its in house CDx Dev unit (Novartis Dx)

Everyone was quoting Yogi Berra....

Denver Summary

Documents

Transcript of Denver Summary